You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameProcyclidine
Accession NumberDB00387  (APRD00383)
TypeSmall Molecule
GroupsApproved
DescriptionA muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. [PubChem]
Structure
Thumb
Synonyms
1-cyclohexyl-1-phenyl-3-pyrrolidin-1-yl-propan-1-ol hydrochloride
1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol
Prociclidina
Procyclidin
Procyclidine
Procyclidinum
Tricyclamol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Kemadrin ElxElixir2.5 mgOralGlaxosmithkline Inc1968-12-312004-08-05Canada
Kemadrin Tab 5mgTablet5 mgOralGlaxosmithkline Inc1956-12-312004-12-02Canada
Pdp-procyclidineElixir2.5 mgOralPendopharm Division Of De Pharmascience Inc1984-12-31Not applicableCanada
Pdp-procyclidineTablet5 mgOralPendopharm Division Of De Pharmascience Inc1985-12-31Not applicableCanada
Pdp-procyclidineTablet2.5 mgOralPendopharm Division Of De Pharmascience Inc1985-12-31Not applicableCanada
Pendo-procyclidineTablet2.5 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PHL-procyclidine TabletsTablet2.5 mgOralPharmel Inc1998-02-172010-11-03Canada
PHL-procyclidine TabletsTablet5 mgOralPharmel Inc1998-02-172010-11-03Canada
Procyclid ElxElixir2.5 mgOralIcn Canada Ltd.1980-12-312005-04-26Canada
Procyclid Tab 5mgTablet5 mgOralIcn Canada Ltd.1974-12-312005-04-26Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArpicolinRosemont
ExtranilGeneral Pharma
KdrineOpsonin
KemadrenGlaxoSmithKline
KemadrinGlaxoSmithKline
OsnervanAspen
ProdinePsyco Remedies
ProimerCho Dang
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Procyclidine hydrochloride
ThumbNot applicableDBSALT001008
Categories
UNIIC6QE1Q1TKR
CAS number77-37-2
WeightAverage: 287.4397
Monoisotopic: 287.224914555
Chemical FormulaC19H29NO
InChI KeyWYDUSKDSKCASEF-UHFFFAOYSA-N
InChI
InChI=1S/C19H29NO/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
IUPAC Name
1-cyclohexyl-1-phenyl-3-(pyrrolidin-1-yl)propan-1-ol
SMILES
OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of all forms of Parkinson's Disease, as well as control of extrapyramidal reactions induced by antipsychotic agents.
Structured Indications
PharmacodynamicsProcyclidine has an atropine-like action on parasympathetic-innervated peripheral structures including smooth muscle. It's antispasmodic effects are thought to be related to the blockage of central cholinergic receptors M1, M2 and M4. It is used to treat symptomatic Parkinsonism and extrapyramidal dysfunction caused by antipsychotic agents.
Mechanism of actionThe mechanism of action is unknown. It is thought that Procyclidine acts by blocking central cholinergic receptors, and thus balancing cholinergic and dopaminergic activity in the basal ganglia. Many of its effects are due to its pharmacologic similarities with atropine. Procyclidine exerts an antispasmodic effect on smooth muscle, and may produce mydriasis and reduction in salivation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M1Proteinyes
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinyes
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M4Proteinyes
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M3Proteinyes
antagonist
HumanP20309 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingApproximately 100% bound to albumin.
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityLD50=60 mg/kg (IV in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Procyclidine.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Procyclidine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Alphacetylmethadol.Experimental, Illicit
AmbenoniumThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Anisotropine Methylbromide.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Atropine.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Procyclidine.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Procyclidine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Procyclidine is combined with Biperiden.Approved
Botulinum Toxin Type AProcyclidine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BProcyclidine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Procyclidine is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Procyclidine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Procyclidine.Approved
CimetropiumProcyclidine may increase the anticholinergic activities of Cimetropium.Experimental
CodeineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Coumaphos.Vet Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Cyclopentolate.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Procyclidine is combined with Darifenacin.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dicyclomine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Diphenoxylate.Approved, Illicit
DonepezilThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Procyclidine is combined with DPDPE.Investigational
DronabinolProcyclidine may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Edrophonium.Approved
EluxadolineProcyclidine may increase the constipating activities of Eluxadoline.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Etorphine.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fesoterodine.Approved
GalantamineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Gallamine Triethiodide.Approved
Ginkgo bilobaThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Procyclidine is combined with Glucagon recombinant.Approved
GlycopyrroniumProcyclidine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Procyclidine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Procyclidine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Procyclidine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hyoscyamine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Procyclidine.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Procyclidine.Approved
IsoflurophateThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Procyclidine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Procyclidine is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Malathion.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Mecamylamine.Approved
MefloquineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Memantine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Methantheline.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Procyclidine.Approved
MetixeneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Procyclidine.Approved
MianserinMianserin may increase the anticholinergic activities of Procyclidine.Approved
MinaprineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Procyclidine is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Morphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Procyclidine is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneProcyclidine may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Normethadone.Approved, Illicit
NVA237The risk or severity of adverse effects can be increased when Procyclidine is combined with NVA237.Investigational
OpiumThe risk or severity of adverse effects can be increased when Procyclidine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Orphenadrine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Procyclidine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pancuronium.Approved
PentazocineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pethidine.Approved
PhysostigmineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Procyclidine.Approved
Potassium ChlorideProcyclidine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Procyclidine.Approved, Investigational
PropanthelineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Propiverine.Investigational
PyridostigmineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Procyclidine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Quinidine.Approved
RamosetronProcyclidine may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Procyclidine is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Scopolamine butylbromide.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Procyclidine.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Procyclidine is combined with Solifenacin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Procyclidine is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Procyclidine.Approved
TacrineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tapentadol.Approved
TiotropiumProcyclidine may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Procyclidine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Procyclidine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Procyclidine is combined with Trimethaphan.Approved
TropicamideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tropicamide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Procyclidine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Procyclidine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Procyclidine is combined with Vecuronium.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Theodoridis GC, Stark L: Central role of solar information flow in pregenetic evolution. J Theor Biol. 1971 Jun;31(3):377-88. [PubMed:5556140 ]
External Links
ATC CodesN04AA04
AHFS Codes
  • 12:08.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9822
Blood Brain Barrier+0.9734
Caco-2 permeable+0.6388
P-glycoprotein substrateSubstrate0.6324
P-glycoprotein inhibitor INon-inhibitor0.51
P-glycoprotein inhibitor IINon-inhibitor0.5877
Renal organic cation transporterInhibitor0.7954
CYP450 2C9 substrateNon-substrate0.7956
CYP450 2D6 substrateNon-substrate0.7907
CYP450 3A4 substrateNon-substrate0.5427
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.915
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.841
CarcinogenicityNon-carcinogens0.9142
BiodegradationNot ready biodegradable0.9178
Rat acute toxicity2.7861 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6498
hERG inhibition (predictor II)Inhibitor0.5597
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Monarch pharmaceuticals inc
PackagersNot Available
Dosage forms
FormRouteStrength
ElixirOral2.5 mg
TabletOral2.5 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Pms-Procyclidine 2.5 mg Tablet0.06USD tablet
Pms-Procyclidine 0.5 mg/ml Elixir0.03USD ml
Pms-Procyclidine 5 mg Tablet0.03USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point86 °CPhysProp
water solubilityModerately soluble in water, ~ 30 mg/mlNot Available
logP4.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00984 mg/mLALOGPS
logP4.13ALOGPS
logP3.79ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)13.84ChemAxon
pKa (Strongest Basic)9.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity88.6 m3·mol-1ChemAxon
Polarizability34.43 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-9010000000-7d7f1b16f54aaca37f10View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Aralkylamine
  • N-alkylpyrrolidine
  • Tertiary alcohol
  • Pyrrolidine
  • 1,3-aminoalcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Larson EW, Pfenning MA, Richelson E: Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart. Psychopharmacology (Berl). 1991;103(2):162-5. [PubMed:2027917 ]
  4. Waelbroeck M, Camus J, Tastenoy M, Lambrecht G, Mutschler E, Tacke R, Christophe J: Stereoselectivity of procyclidine binding to muscarinic receptor subtypes M1, M2 and M4. Eur J Pharmacol. 1990 Sep 18;189(2-3):135-42. [PubMed:2253700 ]
  5. Myhrer T: Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. Neurotoxicology. 2010 Dec;31(6):629-38. doi: 10.1016/j.neuro.2010.07.002. Epub 2010 Jul 17. [PubMed:20624420 ]
  6. Waelbroeck M, Camus J, Tastenoy M, Mutschler E, Strohmann C, Tacke R, Schjelderup L, Aasen A, Lambrecht G, Christophe J: Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42. [PubMed:1426023 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Larson EW, Pfenning MA, Richelson E: Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart. Psychopharmacology (Berl). 1991;103(2):162-5. [PubMed:2027917 ]
  4. Waelbroeck M, Camus J, Tastenoy M, Lambrecht G, Mutschler E, Tacke R, Christophe J: Stereoselectivity of procyclidine binding to muscarinic receptor subtypes M1, M2 and M4. Eur J Pharmacol. 1990 Sep 18;189(2-3):135-42. [PubMed:2253700 ]
  5. Myhrer T: Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. Neurotoxicology. 2010 Dec;31(6):629-38. doi: 10.1016/j.neuro.2010.07.002. Epub 2010 Jul 17. [PubMed:20624420 ]
  6. Waelbroeck M, Camus J, Tastenoy M, Mutschler E, Strohmann C, Tacke R, Schjelderup L, Aasen A, Lambrecht G, Christophe J: Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42. [PubMed:1426023 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Waelbroeck M, Camus J, Tastenoy M, Lambrecht G, Mutschler E, Tacke R, Christophe J: Stereoselectivity of procyclidine binding to muscarinic receptor subtypes M1, M2 and M4. Eur J Pharmacol. 1990 Sep 18;189(2-3):135-42. [PubMed:2253700 ]
  4. Alberts P: Classification of the presynaptic muscarinic receptor subtype that regulates 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. J Pharmacol Exp Ther. 1995 Jul;274(1):458-68. [PubMed:7616431 ]
  5. Myhrer T: Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. Neurotoxicology. 2010 Dec;31(6):629-38. doi: 10.1016/j.neuro.2010.07.002. Epub 2010 Jul 17. [PubMed:20624420 ]
  6. Waelbroeck M, Camus J, Tastenoy M, Mutschler E, Strohmann C, Tacke R, Schjelderup L, Aasen A, Lambrecht G, Christophe J: Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42. [PubMed:1426023 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Myhrer T: Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. Neurotoxicology. 2010 Dec;31(6):629-38. doi: 10.1016/j.neuro.2010.07.002. Epub 2010 Jul 17. [PubMed:20624420 ]
  2. Waelbroeck M, Camus J, Tastenoy M, Mutschler E, Strohmann C, Tacke R, Schjelderup L, Aasen A, Lambrecht G, Christophe J: Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42. [PubMed:1426023 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23